Influenza vaccination and vitamin K antagonist treatment: A placebo-controlled, randomized, double-blind crossover study

Archives of Internal Medicine

Volumn 170, Issue 7, 2010, Pages 609-616

  Iorio, Alfonso ^a   Basileo, Michela ^a   Marcucci, Maura ^a   Guercini, Francesco ^a   Camilloni, Barbara ^a   Paccamiccio, Elisa ^b   Vecchioli, Maria ^b   Iorio, Anna Maria ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Local Health Agency No 2 of Perugia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; PLACEBO; WARFARIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT RESPONSE;

AGED; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; INFLUENZA VACCINES; INTERNATIONAL NORMALIZED RATIO; MALE; PATIENT SELECTION; PLACEBOS; PROTHROMBIN TIME; VACCINATION; WARFARIN;

EID: 77950976169     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.49     Document Type: Article

References (29)

1. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60.
2. Lipsky BA, Pecoraro RE, Roben NJ, de Blaquiere P, Delaney CJ. Influenza vaccination and warfarin anticoagulation. Ann Intern Med. 1984;100(6):835-837.
3. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106. (Pubitemid 40720733)
4. Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med. 1981;305(21):1262-1264. (Pubitemid 12234848)
5. Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J. 1980;123(4):288-290.
6. Gomolin IH. Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly. CMAJ. 1986;135(1):39-41.
7. Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther. 1984;35(3):416-418. (Pubitemid 14174150)
8. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. BMJ. 1995;311(7000):e292. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2550360/?tool=pubmed. Accessed January 27, 2010.
9. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest. 2005;127(1):415-416]. Chest. 2004;126(3)(suppl):204S-233S.
10. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):160S-198S.
11. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC; Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 2002;51(RR-2):1-35.
12. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239. (Pubitemid 23069000)
13. Iorio AM, Camilloni B, Basileo M, et al. Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine. 2006;24(44-46):6624-6628.
14. Commission for Proprietary Medicinal Products. Guidance on Harmonisation of Requirements for Influenza Vaccines. http://www.ema.europa.eu/pdfs/human/bwp/ 021496en.pdf. Accessed March 12, 1997.
15. Putt M, Chinchilli VM. A mixed effects model for the analysis of repeated measures cross-over studies. Stat Med. 1999;18(22):3037-3058. (Pubitemid 29526943)
16. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135-160. (Pubitemid 29425900)
17. Arnold WS, Mehta MK, Roberts JS. Influenza vaccine and anticoagulation control in patients receiving warfarin. Br J Clin Pract. 1990;44(4):136-139.
18. Bussey HI, Saklad JJ. Effect of influenza vaccine on chronic warfarin therapy. Drug Intell Clin Pharm. 1988;22(3):198-201.
19. Jackson ML, Nelson JC, Chen RT, Davis RL, Jackson LA; for the Vaccine Safety Datalink Investigators. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiol Drug Saf. 2007;16(7):790-796.
20. MacCallum P, Madhani M, Mt-Isa S, Ashby D. Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. Pharmacoepidemiol Drug Saf. 2007;16(7):786-789. (Pubitemid 47180367)
21. Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med. 1995;155(14):1529-1531.
22. Souto JC, Oliver A, Montserrat I, Mateo J, Sureda A, Fontcuberta J. Lack of effect of influenza vaccine on anticoagulation by acenocoumarol. Ann Pharmacother. 1993;27(3):365-368. (Pubitemid 23086966)
23. Paliani U, Filippucci E, Gresele P. Significant potentiation of anticoagulation by flu-vaccine during the season 2001-2002. Haematologica. 2003;88(5):599-600.
24. Poli D, Chiarugi L, Capanni M, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis. 2002;13(4):297-300. (Pubitemid 35001869)
25. Weibert RT, Lorentz SM, Norcross WA, Klauber MR, Jagger PI. Effect of influenza vaccine in patients receiving long-term warfarin therapy. Clin Pharm. 1986;5(6):499-503. (Pubitemid 16095730)
26. Poller L, Keown M, Chauhan N, et al. Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. BMJ. 2003;327(7405):e30. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC164241/?tool=pubmed. Accessed January 27, 2010.
27. Sunderji R, Gin K, Shalansky K, et al. Clinical impact of point-of-care vs laboratory measurement of anticoagulation. Am J Clin Pathol. 2005;123(2):184-188. (Pubitemid 40194077)
28. Granier H, Nicolas X, Laborde JP, Talarmin F. Severe autoimmune thrombopenia following anti-influenza vaccination [in French]. Presse Med. 2003;32(26):1223-1224. (Pubitemid 36992837)
29. Schattner A. Consequence or coincidence? the occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23(30):3876-3886. (Pubitemid 40726180)